A list of 20 largest U.S. healthcare mergers and acquisitions announced in 2012, ranked by completed or pending deal's price. Source: Modern Healthcare's 2012 Healthcare M&A Watch series; WNS Global Services. Published Jan. 28, 2013, p. 42.

Read the full story: http://bit.ly/VzsvW6

Source: ModernHealthcare.com

Related Content

Boy with DMD using walker | Image credit: Svitlana – stock.adobe.com

November 23rd 2024

Viltolarsen Slows DMD Progression in Small Study

Hayden E. Klein

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

Tooth loss | Image Credit: © valiantsin-stock.adobe.com

November 23rd 2024

Edentulism May Heighten Sleep Apnea Risk

Jared Kaltwasser

A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 23rd 2024

Health Equity & Access Weekly Roundup: November 23, 2024

Giuliana Grossi

Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.

FDA website | Image Credit: © Postmodern Studio - stock.adobe.com

November 22nd 2024

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Marco Meglio

The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.

Related Content

November 23rd 2024

Viltolarsen Slows DMD Progression in Small Study

Hayden E. Klein

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

November 23rd 2024

Edentulism May Heighten Sleep Apnea Risk

Jared Kaltwasser

A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 23rd 2024

Health Equity & Access Weekly Roundup: November 23, 2024

Giuliana Grossi

November 22nd 2024

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Marco Meglio

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions